Pharmaceuticals News and Research

RSS

Human milk oligosaccharides protect infants against infection

Human milk oligosaccharides - an important ingredient in human breast milk - play a central role in protecting infants against infection. An innovative process developed by Jennewein Biotechnologie GmbH allows for the first time ever the production of these scarce sugar molecules for use as an ingredient in baby food and in additional food products.

13 Oct 2009

EnviroSystems expands its growth opportunities in the Korean market

Anpath Group, Inc., announced today that its wholly-owned subsidiary, EnviroSystems, Inc. (ESI) has expanded its growth opportunities in the Korean market with the appointment of FAB, USA (FAB) as a distributor in Korea. Early this year Anpath announced significant growth in sales of its EnviroTru® Disinfectant Cleaner in Korea.

13 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

TCGRx and NetRx sign partnership to improve the overall process in pharmacies

TCGRx (TCG), an industry leader in automation and design services for pharmacy markets across the U.S., announced today a strategic partnership with NetRx, a national network comprised of locally based, long-term care pharmacies with reputations for personalized service, high-quality products and cost-effective prices.

13 Oct 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

AmexDrug shows positive growth despite poor economic conditions

AmexDrug Corporation, a US pharmaceutical and cosmeceutical company, is showing signs of growth despite poor economic conditions. These increases will be seen for the rest of the year, moving strong into 2010.

13 Oct 2009

Exhibitors display latest biotechnology products and applications at BIOTECHNICA 2009

Chalking up an increase in the number of exhibitors and trade visitors plus the amount of display space sold, the BIOTECHNICA, exhibition (6 to 8 October 2009) sent some important signals in the midst of an economic crisis.

13 Oct 2009

PharmaNet Development to display innovative solutions at 2009 AAPS Annual Meeting and Exposition

PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the Company and its subsidiaries Anapharm and Taylor Technology will be showcasing a range of innovative solutions at the 2009 AAPS Annual Meeting and Exposition.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

The National Committee for Quality Assurance (NCQA), with support from The California Endowment, has recognized five managed care plans for their innovative efforts to improve health care access and quality for consumers facing language and cultural barriers that frequently impede their access to life-prolonging care.

13 Oct 2009

$SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system$

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced that its Pharmorphix® Solid State Research Laboratories in Cambridge, UK, have installed a new single crystal X-ray diffraction system. The Oxford Diffraction SuperNova(TM) system, which can determine the crystal structures from the most challenging crystal samples, is the first industrial installation of this state-of-the-art instrumentation anywhere in the world.

13 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

Phyton Biotech purchases NPI’s assets

Phyton Biotech, LLC (Phyton), an affiliate of Phyton, Inc., today announced that it has purchased the assets of Natural Pharmaceuticals, Inc. (NPI), a leading manufacturer of oncology drug active pharmaceutical ingredients (API’s).

13 Oct 2009

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.

13 Oct 2009

Diagnostics industry in Asia Pacific poised to present more growth opportunities

The global diagnostics industry has witnessed strong growth over the past few years. According to Frost & Sullivan, the diagnostics and monitoring sectors are poised to present more growth opportunities. According to Nitin Naik, Vice President of Frost & Sullivan's Asia Pacific Medical Technologies Division, the diagnostics and monitoring sectors in Asia Pacific are projected to provide more growth opportunities on the basis of the technology spending being channelled in these areas (80 percent).

13 Oct 2009

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Titan Pharmaceuticals, Inc today announced that Vanda Pharmaceuticals, Inc. reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults.

13 Oct 2009

Pharmaceuticals News and Research

Human milk oligosaccharides protect infants against infection

EnviroSystems expands its growth opportunities in the Korean market

Johnson & Johnson announces financial results for the third quarter of 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

TCGRx and NetRx sign partnership to improve the overall process in pharmacies

Pharmaceuticals to provide safe needle collection and disposal programs for patients

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

AmexDrug shows positive growth despite poor economic conditions

Exhibitors display latest biotechnology products and applications at BIOTECHNICA 2009

PharmaNet Development to display innovative solutions at 2009 AAPS Annual Meeting and Exposition

SAFC Pharma expands contract manufacturing services

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Phyton Biotech purchases NPI’s assets

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Diagnostics industry in Asia Pacific poised to present more growth opportunities

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring